HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture

被引:29
作者
Bramlage, B [1 ]
Luzi, E [1 ]
Eckstein, F [1 ]
机构
[1] Max Planck Inst Expt Med, D-37075 Gottingen, Germany
关键词
D O I
10.1093/nar/28.21.4059
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A library of three synthetic ribozymes with randomized arms, targeting NUX, GUX and NXG triplets, respectively, were used to identify ribozyme-accessible sites on the HIV-1 LTR transcript comprising positions -533 to 385. Three cleavable sites were identified at positions 109, 115 and 161. Ribozymes were designed against these sites, either unmodified or with 2'-modifications and phosphorothioate groups, and their cleavage activities of the transcript were determined. Their biological activities were assessed in cell culture, using a HIV-1 model assay system where the LTR is a promoter for the expression of the reporter gene luciferase in a transient expression system. Intracellular efficiency of the ribozymes were determined by cotransfection of ribozyme and plasmid DNA, expressing the target RNA. Modified ribozymes, directed against positions 115 and 161, lowered the level of LTR mRNA in the cell resulting in inhibition of expression of the LTR-driven reporter gene luciferase of 87 and 61%, respectively. In the presence of Tat the inhibitions were 43 and 25%. The inactive variants of these ribozymes exhibited a similar inhibitory effect. RNase protection revealed a reduction of RNA which was somewhat stronger for the active than the inactive ribozymes, particularly for ribozyme 115. Unmodified ribozymes showed no inhibition in the cell. The third ribozyme, targeting a GUG-triplet at position 109, possessed only low cleavage activity in vitro and no inhibitory effect in cell culture.
引用
收藏
页码:4059 / 4067
页数:9
相关论文
共 62 条
[1]   Dose-response resistance to HIV-1/MuLV pseudotype virus ex vivo in a hairpin ribozyme transgenic mouse model [J].
Andäng, M ;
Hinkula, J ;
Hotchkiss, G ;
Larsson, S ;
Britton, S ;
Wong-Staal, F ;
Wahren, B ;
Ährlund-Richter, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (22) :12749-12753
[2]   VECTORS FOR EFFICIENT EXPRESSION IN MAMMALIAN FIBROBLASTOID, MYELOID AND LYMPHOID-CELLS VIA TRANSFECTION OR INFECTION [J].
ARTELT, P ;
MORELLE, C ;
AUSMEIER, M ;
FITZEK, M ;
HAUSER, H .
GENE, 1988, 68 (02) :213-219
[3]   FUNCTIONAL SITES IN THE 5' REGION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA FORM DEFINED STRUCTURAL DOMAINS [J].
BAUDIN, F ;
MARQUET, R ;
ISEL, C ;
DARLIX, JL ;
EHRESMANN, B ;
EHRESMANN, C .
JOURNAL OF MOLECULAR BIOLOGY, 1993, 229 (02) :382-397
[4]   CHEMICAL MODIFICATION OF HAMMERHEAD RIBOZYMES - CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE [J].
BEIGELMAN, L ;
MCSWIGGEN, JA ;
DRAPER, KG ;
GONZALEZ, C ;
JENSEN, K ;
KARPEISKY, AM ;
MODAK, AS ;
MATULICADAMIC, J ;
DIRENZO, AB ;
HAEBERLI, P ;
SWEEDLER, D ;
TRACZ, D ;
GRIMM, S ;
WINCOTT, FE ;
THACKRAY, VG ;
USMAN, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (43) :25702-25708
[5]   TAT TRANS-ACTIVATES THE HUMAN IMMUNODEFICIENCY VIRUS THROUGH A NASCENT RNA TARGET [J].
BERKHOUT, B ;
SILVERMAN, RH ;
JEANG, KT .
CELL, 1989, 59 (02) :273-282
[6]  
Bertrand E, 1997, RNA, V3, P75
[7]  
Birikh KR, 1997, RNA, V3, P429
[8]   The structure, function and application of the hammerhead ribozyme [J].
Birikh, KR ;
Heaton, PA ;
Eckstein, F .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 245 (01) :1-16
[9]   Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake [J].
Bramlage, B ;
Alefelder, S ;
Marschall, P ;
Eckstein, F .
NUCLEIC ACIDS RESEARCH, 1999, 27 (15) :3159-3167
[10]   Designing ribozymes for the inhibition of gene expression [J].
Bramlage, B ;
Luzi, E ;
Eckstein, F .
TRENDS IN BIOTECHNOLOGY, 1998, 16 (10) :434-438